Medtronic (MDT) announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with Heart Failure with preserved Ejection Fraction. Physicians routinely use pacing therapy to treat patients whose hearts beat too slowly. This study, however, will investigate a potential novel treatment for patients with HFpEF by using conduction system pacing to improve patient outcomes and heart failure symptoms. Medtronic intends to use the study results to pursue a new pacing indication for patients with HFpEF who currently have limited clinically proven treatments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strategic Growth Focus and Portfolio Optimization Drive Buy Rating
- Medtronic’s Cardiac Device Study: A Key Update for Investors
- Medtronic’s Product Surveillance Registry: A Commitment to Safety and Effectiveness
- Medtronic’s Innovative Pacemaker Study: A New Frontier in Hypertension Treatment
- Insider Moves: Medtronic, AST SpaceMobile, Take-Two, Lyft, Sunrun